AI assistant
Sending…
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2024
Jul 1, 2024
34113_dirs_2024-07-01_6474e7e2-c4d2-4442-a636-810d7e20bea4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ATOSSA THERAPEUTICS, INC. (ATOS)
CIK: 0001488039
Period of Report: 2024-06-27
Reporting Person: Rees Heather (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-27 | Stock Option (right to buy) | $1.05 | A | 577700 | Acquired | 2034-06-27 | Common Stock (577700) | Direct |
Footnotes
F1: The options shall vest on a quarterly basis over 24 months following June 27, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024, with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024.
More from ATOSSA THERAPEUTICS, INC.
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 8
Declaration of Voting Results & Voting Rights Announcements
2026
May 8
Regulatory Filings
2026
Apr 16
Director's Dealing
2026
Mar 31
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 20
Capital/Financing Update
2026
Feb 20
Delisting Announcement
2026
Feb 17
Regulatory Filings
2026
Feb 11